Anna E Crivici

Title: Anna E Crivici: Innovator in Gastrointestinal Therapeutics

Introduction

Anna E Crivici is a notable inventor based in Toronto, Canada. She has made significant contributions to the field of gastrointestinal therapeutics, particularly through her research on glucagon-like peptide-2 (GLP-2) analogs. Despite having no patents to her name, her work has been influential in understanding intestinal tissue growth factors.

Latest Patents

Anna's latest patents include the development of glucagon-like peptide-2 analogs. These analogs, products of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation for pharmaceutical and therapeutic use in treating disorders of the small bowel is described in her work. Additionally, she has identified antagonists of GLP-2 peptides, detailing their effects on the growth of gastrointestinal tissue. The formulation of these antagonists for pharmaceutical use and their therapeutic applications in treating bowel tissue are also outlined. Furthermore, she has described methods for identifying antagonists of glucagon-like peptide-2.

Career Highlights

Throughout her career, Anna has worked with various companies, including 1149336 Ontario, Inc. and NPS Pharmaceuticals, Inc. Her research has contributed to advancements in the understanding and treatment of gastrointestinal disorders.

Collaborations

Anna has collaborated with notable individuals in her field, including Daniel J Drucker and Martin Sumner-Smith. These collaborations have furthered her research and expanded the impact of her work.

Conclusion

Anna E Crivici is a dedicated inventor whose research on glucagon-like peptide-2 has the potential to transform therapeutic approaches for gastrointestinal disorders. Her contributions, although not patented, are significant in the scientific community.